奧麥羅製藥 OMER 深 滬
等待開盤 11-04 09:30:00 美东时间
18.27
+0.440
+2.47%
華盛通- 最 高18.40
- 今 開18.08
- 成交量 88.74万股
- 最 低 17.86
- 昨 收 17.83
- 總市值 13.23亿
- 52周最高 21.2399
- 市盈率 靜 --
- 換手率 1.23%
- 52周最低 6.7023
- 委 比 -50.93%
- 總股本 7238.83万
- 歷史最高 30.23
- 量 比 0.64
- 振 幅 3.03%
- 歷史最低 0.92
- 每 手 1
- 風險率 3.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多奥麦罗制药收跌3.31%，成交额1623.55万美元
11月3日，奥麦罗制药（OMER）收跌3.31%，报17.83美元，成交额1623.55万美元，市值12.91亿美元。 行情数据 • 开盘价：18.45美元 ...
11-03 06:37
Omeros Grants CEO New Performance-Based Stock Options
Omeros ( ($OMER) ) has shared an update. On October 28, 2026, Omeros’ board com...
10-31 05:39
奥麦罗制药收跌1.69%，成交额1214.99万美元
10月27日，奥麦罗制药（OMER）收跌1.69%，报16.29美元，成交额1214.99万美元，市值11.79亿美元。 行情数据 • 开盘价：16.78美元...
10-27 05:41
奥麦罗制药收跌13.78%，成交额6478.95万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:43
Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Decision follows re-examination of its original negative opinion adopted in June 2026. An eight-member ad hoc expert group (AHEG) consisting of hematologists, statisticians, and transplant physicians, together with two patient representatives, was convened by CHMP as part of the re-examination proce...
10-16 18:22
美股大行评级 | 潜在涨幅325.53%！HC Wainwright维持Alector"买入"评级，目标价上调至8美元
今日重点评级关注：HC Wainwright & Co.：维持Alector"买入"评级，目标价从5美元升至8美元；摩根大通：维持ORIC Pharmaceuticals"超配"评级，目标价从23美元升至26美元
10-15 12:36
Cantor Fitzgerald Reiterates Overweight on Omeros, Maintains $22 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Omeros (NASDAQ:OMER) with a Overweight and maintains $22 price target.
10-14 18:43
美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst
Cantor Fitzgerald on Tuesday upgraded Omeros Corp (NASDAQ:OMER), citing a better-than-expected Yartemlea launch. Cantor changed the rating from Neutral to Overweight and reinstated the price target of $22, and wrote, “We’re increasingly convinced this could also be a bigger drug than we appreciated....
09-23 01:51
Omeros upgraded at Cantor on Yartemlea opportunity
Shares of Omeros Corporation (OMER) set a new 52-week high on Tuesday after Cantor Fitzgerald upgraded the biotech to Overweight from Neutral, citing bigger-than-anticipated sales prospects for its ne...
09-23 01:07
